Search for: "SmithKline Beecham"
Results 1 - 20
of 438
Sort by Relevance
|
Sort by Date
31 Jul 2023, 1:47 pm
” SmithKline Beecham Corp. v. [read post]
11 Apr 2023, 2:44 pm
” SmithKline Beecham Corp. v. [read post]
10 Feb 2023, 4:44 am
Putting aside the idiosyncratic chapter by the late Professor Berger, most of the third edition of the Reference Manual presented guidance on many important issues. [read post]
19 Jan 2023, 1:46 pm
See SmithKline Beecham Corp. v. [read post]
24 Oct 2022, 8:54 am
The following is a guest post from Logan Moore. [read post]
19 Jul 2022, 6:14 am
A few egregious articles in the biomedical literature have begun to endorse explicitly asymmetrical standards for inferring causation in the context of environmental or occupational exposures. [read post]
10 Jun 2022, 10:38 am
Cir. 2013) (citing SmithKline Beecham Corp. v. [read post]
12 Dec 2021, 2:22 pm
In assessing an association for causality, the starting point is “an association between two variables, perfectly clear-cut and beyond what we would care to attribute to the play of chance. [read post]
15 Oct 2021, 9:43 am
Smithkline Beecham Corp. [read post]
5 Aug 2021, 12:12 pm
The outcome was a vacating of the district court's grant of JMOL and a lot of discussion of drug "skinny labels": GlaxoSmithKline LLC and SmithKline Beecham (Cork) Ltd. [read post]
1 Mar 2021, 6:18 am
SmithKline Beecham Clinical Lab., 950 F. [read post]
4 Dec 2020, 6:13 am
SmithKline Beecham Clinical Lab., 950 F. [read post]
23 Jun 2020, 1:01 pm
Smithkline Beecham Clinical Labs., Inc., 863 So. 2d 201, 208–09 (Fla. 2003). [read post]
23 Jun 2020, 1:01 pm
Smithkline Beecham Clinical Labs., Inc., 863 So. 2d 201, 208–09 (Fla. 2003). [read post]
20 Apr 2020, 5:01 am
Adverse event reporting is a recognized, important component of pharmacovigilence. [read post]
9 Mar 2020, 3:19 pm
” Synthon BV v SmithKline Beecham plc [2006] RPC 10 (Lord Hoffman). [read post]
28 Nov 2019, 12:57 pm
The opponents argued that GSK had failed to provide evidence that, on the filing date of the PCT, the right to claim priority had been transferred from the inventor-applicants of P1 and P2 (Mr O’Neill and Mr Bush) to Smithkline Beecham Corporation (SBC) (for more on assignment of priority rights, see IPKat: Assigned or not assigned). [read post]
3 Nov 2019, 9:04 pm
” SmithKline Beecham Corp. v. [read post]
24 Oct 2019, 10:40 am
SmithKline Beecham Corp., 567 U.S. 142 (2012). [read post]
14 Jul 2019, 5:03 pm
SmithKline Beecham Corp., 567 US 142, 155 (2012) which was further quoting Bowen v. [read post]
